Strasbourg, France, 2 August 2022 – Polyplus, a leading upstream solutions provider for advanced biologic and cell and gene therapy production from research to commercial grade, today announces the availability of Transgene Plasmid Engineering Services for viral vector manufacturing. The expansion of plasmid services can be used stand alone, or as a complement to the industry standard PEIpro® and FectoVIR-AAV® reagents and kits for next generation viral vector and gene therapy manufacturing.
Following the early 2022 acquisition of e-Zyvec, integration activities have focused on providing a deeper level of solutions support to customers. Using the proprietary e-Zyvec technology, plasmids are assembled de novo, from a library of DNA bricks, removing the use of standard backbones that contain undesired DNA sequences. Plasmids can be engineered from scratch in a record short time window of only two weeks using the Polyplus online plasmid engineering tool. These engineered plasmids can then be chosen for the delivery of the gene of interests used in gene therapies.
“We are now one of few companies in the market that can provide a fully customizable plasmid engineering service,” said Mario Philips, CEO at Polyplus. ““This innovative and rapid plasmid engineering services will help the Viral Vector industry to optimize process economics for advanced therapy manufacturing and enable customers to achieve their ambitious Time to Market goals.”
“The Transgene Plasmid Engineering Services are a great complement to the existing transfection reagent portfolio. We can support customers in the design and optimisation of their transgene, before it is transfected in producing cells for viral vector production.” Sylvain Julien, Innovation Director at Polyplus commented. “Throughout each step of the process, we are working in close relation with our customers to make sure that the final plasmid design will fit their expectations.”
Transgene Services are currently available to engineer custom plasmids for viral vector manufacturing processes. An online portal (D-Zyvec) enables interested parties initiate a project and start drawing their ideal plasmid. The drawings are moved into an interaction with Polyplus experts to evaluate feasibility, enhance design, and deliver best-in-class plasmids for the process. The from scratch engineered plasmids can be available in a period of only two weeks.
Polyplus is a leading upstream solutions provider for advanced biologic and cell and gene therapy production from research to commercial scale. An innovator in nucleic acid delivery, the legacy portfolio features process-centric transfection reagents, kits, and support services including bioproduction industry standard, PEIpro®. Custom plasmid vector design was integrated into the offer in 2022 as a first measure to expanding the products and services portfolio to help the industry optimize process economics while meeting strict scientific and regulatory standards. Headquartered in Europe, the Polyplus team continues to grow globally with operations in the United States and Asia. Learn more at www.polyplus-transfection.com.
Media Contact Information:
Alengo Nyamay’antu, PhD
Scientific Communication Specialist at Polyplus
Direct: +33 3 88 67 59 38